Business Wire

New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance

30.9.2020 09:00:00 EEST | Business Wire | Press release

Share

Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/

“Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of The Forrester WaveTM: Enterprise Data Fabric, Q2 2020. The report also states, “Denodo is known for data virtualization, and over the years it has also evolved into a data fabric vendor. Denodo’s data fabric solution integrates key data management components, including data integration, data ingestion, data transformation, data governance and security, to support new and emerging use cases including customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI/ML capabilities, as well as automation, continue to enhance its capabilities across data fabric components.”

Through data virtualization, the Denodo Platform offers enterprise-grade data integration, management, and delivery that rivals legacy data integration techniques. The new version of the Denodo Platform advances agile data integration and governed data management, extending Denodo’s reach into advanced hybrid and multicloud architectures and new data science use cases.

“Denodo 8.0 packs key capabilities that are essential for our Decision Support Initiative,” said Dan Young, chief data architect and manager at Indiana University, Bloomington. “Our mission is to provide timely, relevant, and accurate data for better decision making to our executives and faculty. The Denodo Platform has been a key technology in our logical data fabric architecture, integrating student and enrollment, personnel, and financial data, and delivering the unified information to our Academics Metrics (AM) 360 dashboards. With it, decision makers at Indiana University have been able to successfully measure, compare, and analyze trends regarding the health of their responsibility centers.”

Key functionalities of Denodo Platform 8.0 include:

  • Hybrid cloud/multicloud integration: Denodo Platform 8.0 enables organizations to accelerate data integration across different locations while lowering operational costs and leveraging platform-as-a-service (PaaS)-style infrastructure automation and autoscaling support.
  • Machine learning/data science automation: An ML-aided data catalog helps data scientists discover and prepare data for building complex data models and aids in supporting advanced analytics. With the integrated Apache Zeppelin Notebook, they can construct narratives combining queries with code, text, and graphics, and share it with fellow data scientists.
  • API/microservices enhancements: New support for execution of GraphQL on top of logical data models promotes no-code approach to the use of REST APIs and accelerates the adoption of advanced microservices architectures.
  • Hyper performance: Denodo Platform 8.0 maximizes query delegation and boosts performance to sub-second responses with AI-powered recommendations, advanced caching, and smart query acceleration for frequent, expensive queries.
  • Unified Web-based UI with Single Sign-On: Newly introduced interface unifies all design and runtime tools with single sign-on support facilitating rapid design, development, deployment, and management processes.

“Denodo 8.0 is the result of years of continuous innovation to support our customers’ enterprise data management journeys,” said Alberto Pan, executive vice president and chief technology officer at Denodo. “Our customers have been pioneers in their respective industries, leveraging the Denodo Platform as the enterprise logical data fabric for advanced analytics, cloud modernization, data science, and data services. We responded to our customers’ requests by providing the most advanced data platform in the industry with PaaS-style infrastructure management, machine learning data catalog, GraphQL support, smart query acceleration, and an easy-to-use unified user interface.”

Recently, Denodo was named a Leader in the 2020 Gartner Magic Quadrant for Data Integration Tools.

Please Tweet: News: @denodo announces new Denodo Platform 8.0. Latest version supports advanced #DataVirtualization #DataFabric #HybridCloud #Multicloud #ML #AI #Microservices capabilities.

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, and cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye